Medtronic launched the wireless, adhesive heart monitor that it acquired when it bought startup Corventis in June reportedly for more than $150 million. The monitor can be worn up to 30 days to detect and diagnose the cause of irregular heartbeats. But the device remains a second-line tool behind the bulky Holter monitor.
Hospitals affiliated with Stanford and Duke University are initiating partnerships with Apple and its yet to be unveiled HealthKit, designed to collect data from healthcare apps and present it to doctors in a centralized location.
Rather than rely on phone and fax, the two hospitals hope to collect diabetics' blood sugar information via an iPod Touch, Reuters reports.
It was the best of times and the worst of times for med tech CEOs in 2013. Medical device outfits faced a chilly regulatory climate, with product approvals reaching a new low and the 2.3% device tax threatening to damage each company's bottom line. As a result, sales and R&D took a substantial hit--and CEOs responded with a new plan of attack. With industry veterans at the helm of each company, med tech outfits managed to outrun nagging legal woes, win critical devices approvals, generate M&A--and in some cases, post a profit.
POPULAR COMMENT THREADS
Former Alere executives are putting together a $46-per-share takeover offer for the diagnostics company, according to a Sept. 15 SEC filing. Investors didn't embrace the offer entirely, but they did send shares up about 13% to $41.33 in midafternoon trading.
St. Jude Medical has halted implantation of its Portico transcatheter aortic valve replacement due to concerns about reduced valve leaflet mobility arising from the company's U.S. clinical trials. The CE-marked device is intended for patients with severe aortic stenosis who are at high risk or contraindicated for surgical aortic valve replacement.
Amid mounting industry pressure to unveil a therapy to counter the deadly Ebola outbreak, researchers are developing an innovative dialysis device that fights the disease by filtering blood.
Corindus Vascular Robotics has raised $26.6 million in a private placement to help it market its FDA approved CorPath Vascular Robotic System. This is the first FDA-approved device to apply robotics to coronary angioplasties; the agency cleared it in 2012 to be used in percutaneous coronary interventions (PCI).
Stent developer Amaranth Medical is launching the MEND-II clinical trial to test its Fortitude Sirolimus-Eluting Bioresorbable Scaffold, a sign that companies large and small are keenly the new treatment paradigm for coronary artery disease involving stents that disintegrate within the body after a couple of years.
Early cancer screening is causing a rise of unnecessarily aggresive treatments for non-serious abnormalities. But reducing early screening isn't much of an option either, with over half a million Americans dying from cancer annually, many from fast-developing cancers that spread quickly between screenings.
From Our Sister Sites
Roche is again tracking down counterfeits of some of its cancer meds in Europe after an importer in Germany discovered the fakes. In this case, it is counterfeit MabThera, sold as Rituxan in the U.S.
Takeda didn't bring on non-Japanese COO Christophe Weber for nothing. The Osaka-based drugmaker, still faltering in the wake of its patent loss on diabetes champ Actos, was looking for a shake-up. And now, as promised, the blueprints for a new, reorganized company structure are here.